{"log_id": 2817810353090533992, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.000102, "average": 0.995923, "min": 0.951009}, "location": {"width": 737, "top": 235, "height": 28, "left": 255}, "words": "胃肠道:本品用药期间报道有恶心、呕吐及腹泻。胃肠道不良反应主要发生在治疗的开"}, {"probability": {"variance": 9.9e-05, "average": 0.994799, "min": 0.949018}, "location": {"width": 572, "top": 282, "height": 26, "left": 213}, "words": "始阶段,通过与食物或饮料同服或者缓慢增加剂量可基本加以控制"}, {"probability": {"variance": 2.2e-05, "average": 0.997371, "min": 0.979247}, "location": {"width": 437, "top": 342, "height": 26, "left": 254}, "words": "皮肤和皮下组织:罕见瘙痒和皮疹等皮肤过敏反应"}, {"probability": {"variance": 0, "average": 0.999453, "min": 0.999318}, "location": {"width": 45, "top": 403, "height": 25, "left": 253}, "words": "检查"}, {"probability": {"variance": 5.1e-05, "average": 0.996113, "min": 0.970786}, "location": {"width": 668, "top": 447, "height": 28, "left": 254}, "words": "可能出现一过性肝转氨酶和碱性磷酸酶增高。已有γ谷氨酰转移酶升高的报道"}, {"probability": {"variance": 1e-06, "average": 0.998963, "min": 0.996801}, "location": {"width": 342, "top": 493, "height": 26, "left": 251}, "words": "发现在本品用药期间血液中尿素氮升高"}, {"probability": {"variance": 1.7e-05, "average": 0.997716, "min": 0.977665}, "location": {"width": 741, "top": 537, "height": 28, "left": 252}, "words": "尿液颜色可见改变,通常为淡红色,静置后颜色变深。其他体液或组织,包括唾液、舌"}, {"probability": {"variance": 7.1e-05, "average": 0.995272, "min": 0.968932}, "location": {"width": 398, "top": 572, "height": 30, "left": 211}, "words": "头、牙齿和口腔黏膜,颜色也可能变浅或变深"}, {"probability": {"variance": 0.000969, "average": 0.993443, "min": 0.804678}, "location": {"width": 738, "top": 624, "height": 26, "left": 255}, "words": "国外已有患者使用多巴胺受体激动剂类药品治疗帕金森病后出现病理性赌博、性欲增高"}, {"probability": {"variance": 0.003394, "average": 0.987761, "min": 0.648668}, "location": {"width": 690, "top": 668, "height": 28, "left": 211}, "words": "和性欲亢进的病例报告,尤其在高剂量时,在降低治疗剂量或停药后一般可逆转"}, {"probability": {"variance": 2e-06, "average": 0.999012, "min": 0.996415}, "location": {"width": 67, "top": 714, "height": 26, "left": 221}, "words": "【禁忌】"}, {"probability": {"variance": 0, "average": 0.762854, "min": 0.762854}, "location": {"width": 88, "top": 691, "height": 46, "left": 857}, "words": " PHARM"}, {"probability": {"variance": 2.2e-05, "average": 0.994511, "min": 0.989806}, "location": {"width": 196, "top": 725, "height": 57, "left": 787}, "words": "制药"}, {"probability": {"variance": 1.6e-05, "average": 0.997692, "min": 0.982717}, "location": {"width": 597, "top": 768, "height": 31, "left": 252}, "words": "本品禁用于已知对左旋多巴、苄丝肼或其赋型剂过敏的患者"}, {"probability": {"variance": 0, "average": 0.778186, "min": 0.778186}, "location": {"width": 73, "top": 790, "height": 35, "left": 771}, "words": "("}, {"probability": {"variance": 0.013061, "average": 0.964945, "min": 0.500701}, "location": {"width": 736, "top": 834, "height": 27, "left": 252}, "words": "禁止将本品与非选择性单胺氧化酶抑制剂合用,但选择性单氧化酶B抑制剂(如司"}, {"probability": {"variance": 0.013632, "average": 0.968259, "min": 0.463966}, "location": {"width": 761, "top": 876, "height": 31, "left": 211}, "words": "来吉兰和雷沙吉兰)和选择性单胺氧化酶A抑制剂(如吗氯贝胺)则不在禁止合用之冽"}, {"probability": {"variance": 0.003185, "average": 0.986925, "min": 0.64863}, "location": {"width": 781, "top": 926, "height": 26, "left": 211}, "words": "合用单胺氧化酶A与单胺氧化酶B抑制剂相当于非选择性单胺氧化酶抑制剂,因而不应与"}, {"probability": {"variance": 0.001, "average": 0.987763, "min": 0.864274}, "location": {"width": 320, "top": 972, "height": 25, "left": 211}, "words": "本品联合应用(见【药物相互作用】)"}, {"probability": {"variance": 0.000639, "average": 0.994263, "min": 0.841742}, "location": {"width": 739, "top": 1032, "height": 26, "left": 252}, "words": "本品禁用于以下疾病的失代偿期:内分泌疾病、肾功能损害(不宁腿综合症透析患者除"}, {"probability": {"variance": 0.000688, "average": 0.990778, "min": 0.847123}, "location": {"width": 779, "top": 1077, "height": 28, "left": 212}, "words": "外)、肝功能损害或心脏疾病。禁用于精神类疾病、闭角型青光眼的患者。(注:本品尚未在"}, {"probability": {"variance": 0.00018, "average": 0.993817, "min": 0.960114}, "location": {"width": 276, "top": 1124, "height": 25, "left": 214}, "words": "中国批准不宁腿综合症的适应症"}, {"probability": {"variance": 8e-06, "average": 0.998371, "min": 0.988976}, "location": {"width": 519, "top": 1183, "height": 25, "left": 253}, "words": "本品禁用于25岁以下的患者(必须是骨骼发育完全的患者)"}, {"probability": {"variance": 0.004483, "average": 0.981084, "min": 0.648313}, "location": {"width": 736, "top": 1242, "height": 26, "left": 253}, "words": "本品禁用于妊娠期以及未采用有效避孕措施的有潜在妊娠可能的妇女(见【孕妇及哺乳"}, {"probability": {"variance": 0.003703, "average": 0.986397, "min": 0.638235}, "location": {"width": 645, "top": 1286, "height": 27, "left": 212}, "words": "期妇女用药】)。如患者在用药期间怀孕,应停止用药(根据处方医师建议)"}, {"probability": {"variance": 0, "average": 0.999491, "min": 0.998653}, "location": {"width": 107, "top": 1334, "height": 23, "left": 222}, "words": "【注意事项】"}, {"probability": {"variance": 0.082648, "average": 0.704295, "min": 0.416809}, "location": {"width": 115, "top": 1315, "height": 56, "left": 892}, "words": "份"}, {"probability": {"variance": 0.001028, "average": 0.985696, "min": 0.835087}, "location": {"width": 738, "top": 1375, "height": 28, "left": 253}, "words": "本品若与拟交感神经药物(如肾上腺素,去甲肾上腺素,异丙肾上腺素,安非他等)"}, {"probability": {"variance": 6e-06, "average": 0.998881, "min": 0.984896}, "location": {"width": 778, "top": 1422, "height": 27, "left": 213}, "words": "同时使用,可能会增强这类药物作用,故不推荐与拟交感神经药物的联合用药。如果必须联"}, {"probability": {"variance": 7e-06, "average": 0.998391, "min": 0.987127}, "location": {"width": 608, "top": 1467, "height": 27, "left": 214}, "words": "合用药,必须密切监视心血管系统,且拟交感神经药物的剂量需要减少"}, {"probability": {"variance": 0.002187, "average": 0.99021, "min": 0.707494}, "location": {"width": 739, "top": 1511, "height": 28, "left": 252}, "words": "其他抗帕金森药物可与本品联合用药。如正在接受其他抗帕金森药物的治疗(如抗胆碱"}, {"probability": {"variance": 0.000215, "average": 0.989463, "min": 0.959629}, "location": {"width": 120, "top": 1576, "height": 22, "left": 543}, "words": "第4页/共11页"}], "language": 3}